[go: up one dir, main page]

WO1996036881A3 - Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh) - Google Patents

Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh) Download PDF

Info

Publication number
WO1996036881A3
WO1996036881A3 PCT/GB1996/001165 GB9601165W WO9636881A3 WO 1996036881 A3 WO1996036881 A3 WO 1996036881A3 GB 9601165 W GB9601165 W GB 9601165W WO 9636881 A3 WO9636881 A3 WO 9636881A3
Authority
WO
WIPO (PCT)
Prior art keywords
tcr
mhc
peptide ligand
responder cells
signal produced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1996/001165
Other languages
English (en)
Other versions
WO1996036881A2 (fr
Inventor
Dan Hung Barouch
Stephen John Rupert Vessey
Bent Karsten Jakobsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Priority to AU57690/96A priority Critical patent/AU5769096A/en
Publication of WO1996036881A2 publication Critical patent/WO1996036881A2/fr
Publication of WO1996036881A3 publication Critical patent/WO1996036881A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne les interactions entre les RLT et leur ligand CMH-peptide spécifique. Un procédé d'évaluation préliminaire permet d'identifier les substances qui inhibent l'interaction spécifique entre le RLT et un ligand CMH-peptide: il consiste à incuber des cellules sensibles exprimant un RLT avec (i) un ligand CMH-peptide qui stimule ces cellules sensibles et (ii) une substance potentiellement inhibitrice; à mesurer le signal produit par les cellules sensibles quand le RLT entre en contact avec le ligand CMH-peptide; et à comparer le signal produit par ces cellules sensibles, lors du contact du RLT avec le ligand CMH-peptide, avec un signal de référence obtenu avec les mêmes cellules sensibles lorsqu'elles sont incubées avec (i) mais sans (ii). La diminution du signal associée à la présence de (ii) dans le milieu d'incubation représente l'efficacité de l'inhibiteur.
PCT/GB1996/001165 1995-05-16 1996-05-16 Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh) Ceased WO1996036881A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU57690/96A AU5769096A (en) 1995-05-16 1996-05-16 Screening for inhibitors of tcr-mhc interactions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509844.8A GB9509844D0 (en) 1995-05-16 1995-05-16 Screening for inhibitors of TCR-MHC interactions
GB9509844.8 1995-05-16

Publications (2)

Publication Number Publication Date
WO1996036881A2 WO1996036881A2 (fr) 1996-11-21
WO1996036881A3 true WO1996036881A3 (fr) 1997-01-09

Family

ID=10774510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001165 Ceased WO1996036881A2 (fr) 1995-05-16 1996-05-16 Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh)

Country Status (3)

Country Link
AU (1) AU5769096A (fr)
GB (1) GB9509844D0 (fr)
WO (1) WO1996036881A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031625A1 (fr) 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides presentant un domaine fonctionnel important, et leurs procedes d'identification et d'utilisation
US6309820B1 (en) 1995-04-07 2001-10-30 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
AU3036597A (en) * 1996-05-21 1997-12-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells
AU2481399A (en) * 1998-01-29 1999-08-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Variant peptide ligands that selectively induce apoptosis
US20040253632A1 (en) * 2000-05-25 2004-12-16 Sunol Molecular Corporation Modulation of T -cell receptor interactions
US20210371849A1 (en) * 2018-07-31 2021-12-02 Janux Therapeutics, Inc. Inhibitory t cell receptor peptides and discovery methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016234A1 (fr) * 1991-03-22 1992-10-01 The Trustees Of The University Of Pennsylvania Procede de modulation de la reaction de lymphocytes t de mammiferes
WO1995007707A1 (fr) * 1993-09-14 1995-03-23 Cytel Corporation Alteration de la reponse immunitaire a l'aide de peptides se liant a des alleles pan dr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016234A1 (fr) * 1991-03-22 1992-10-01 The Trustees Of The University Of Pennsylvania Procede de modulation de la reaction de lymphocytes t de mammiferes
WO1995007707A1 (fr) * 1993-09-14 1995-03-23 Cytel Corporation Alteration de la reponse immunitaire a l'aide de peptides se liant a des alleles pan dr

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. MADRENAS ET AL.: "Zeta phosphorylation without ZAP-70 activation induced by TcR antagonists or partial agonists.", SCIENCE, vol. 267, no. 5197, 27 January 1995 (1995-01-27), WASHINGTON, DC, USA, pages 515 - 518, XP002015729 *
S. JAMESON ET AL.: "Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, no. 6, 1 June 1993 (1993-06-01), NEW YORK, NY, USA, pages 1541 - 1550, XP000604978 *
S. WEBER ET AL.: "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor.", NATURE, vol. 356, 30 April 1992 (1992-04-30), LONDON, GB, pages 793 - 796, XP002008364 *
W. WILLIAMS ET AL.: "Modulation of T cell responses with MHC-derived peptides.", IMMUNOLOGICAL RESEARCH, vol. 11, no. 1, March 1992 (1992-03-01), BASEL, SWITZERLAND, pages 11 - 23, XP002015728 *

Also Published As

Publication number Publication date
AU5769096A (en) 1996-11-29
WO1996036881A2 (fr) 1996-11-21
GB9509844D0 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
AU3538195A (en) Assays and devices for the detection of extrahepatic biliary atresia
WO2000021987A3 (fr) Methode d'identification de modulateurs de recepteurs de membranes de surface cellulaire s'utilisant dans le traitement de maladies
AU2610101A (en) Methods and systems for monitoring intracellular binding reactions
MX9803774A (es) Metodo para la cuantificacion de material biologico en una muestra.
AU5690694A (en) Human cyclooxygenase-2cdna and assay for evaluating inhibition of cyclooxygenase-2
NZ306051A (en) Testing using electrochemiluminescence
AU7974987A (en) Immunoassay based on two ensyme inhibition system
WO1996036881A3 (fr) Evaluation preliminaire d'inhibiteurs potentiels des interactions entre les recepteurs des lymphocytes t (rlt) et le complexe majeur d'histocompatibilite (cmh)
Yu et al. Antigen-and ionophore-induced signal transduction in rat basophilic leukemia cells involves protein tyrosine phosphorylation.
ATE324462T1 (de) Assays zur detektierung von modulatoren der cytoskeletalen funktion
WO2005059163A3 (fr) Procedes, compositions et trousses pour analyser l'activite enzymatique dans des cellules
NO972707L (no) Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon
CA2204305A1 (fr) Appareil et methode de determination de la couleur d'un echantillon d'urine
MX9709360A (es) Metodo para la deteccion de compuestos que modulan los efectos de la proteina de la obesidad.
Abgrall et al. Variation of Weddell seal (Leptonychotes weddellii) underwater vocalizations over mesogeographic ranges
WO2000077241A3 (fr) Recherche d'heparanase
ATE333511T1 (de) Auf sporenauskeimung basierendes analytisches system
ATE223045T1 (de) Inhibierung der amulin-freisetzung
WO1999019506A3 (fr) Methode d'identification de ligands a liaison optimale avec un recepteur
WO2002037077A3 (fr) Techniques de criblage reposant sur un systeme d'analyse de regulation transcriptionnelle au moyen de lignees cellulaires transformees
WO1999055901A3 (fr) Technique de criblage fonctionnel de grande capacite servant a identifier des ligands de purinorecepteurs humains
WO2003102154A3 (fr) Improved receptor detection
NZ335489A (en) Method for the detection of compounds that modulate the effects of the obese (OB) protein
AU6647490A (en) Enzyme assay and assay kit to measure cellular activation
Ashley et al. Evidence for a K+ channel in bovine chromaffin granule membranes: single-channel properties and possible bioenergetic significance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase